What are the contraindications for Engerix (hepatitis B vaccine)?

Engerix Contraindications

Engerix-B is contraindicated in persons with hypersensitivity to yeast or any vaccine component, and in those with previous hypersensitivity to any hepatitis B-containing vaccine. 1

Absolute Contraindications

The FDA-approved drug label and ACIP guidelines consistently identify two absolute contraindications:

• History of hypersensitivity to yeast (Saccharomyces cerevisiae/baker's yeast) 1, 2, 3
• Previous hypersensitivity to any hepatitis B-containing vaccine 1
• History of anaphylaxis after a previous dose of hepatitis B vaccine - these persons should not receive additional doses 2, 3, 4

Notably, despite theoretical concerns about yeast allergy, no documented evidence exists of adverse reactions in persons with yeast allergy history who received the vaccine 2, 3. However, the contraindication remains in place as a precautionary measure.

Precautions (NOT Contraindications)

The following are precautions requiring deferral, not absolute contraindications:

• Moderate or severe acute illness (with or without fever) - defer until illness resolves 2, 3, 4, 1

Common Misconceptions - What is NOT Contraindicated

Critical clinical pitfall: Many conditions are incorrectly assumed to be contraindications. The evidence explicitly states vaccination is NOT contraindicated in:

• Pregnancy - Limited data show no apparent risk to developing fetuses; vaccines contain noninfectious HBsAg 2, 3, 4, 5
• Multiple sclerosis - No causal association demonstrated despite rare temporal associations 2, 3, 4, 5
• Guillain-Barré syndrome - Evidence insufficient to establish causal relationship 3, 4, 5
• Autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis) 2, 3, 4, 5
• Other chronic diseases 2, 3, 4
• Minor illnesses (mild upper respiratory infections with or without low-grade fever) 1

Safety Context

The incidence of anaphylaxis is extremely rare at approximately 1 case per 1.1 million doses in children and adolescents 6, 5. The vaccine has demonstrated an excellent safety profile across 30 years of use in over 120 million recipients in the United States alone 2, 7.

Special Populations Requiring Clinical Judgment

• Immunosuppressed persons or those on immunosuppressive therapy - Not contraindicated, but may have reduced immune response; consider deferring vaccination for at least 3 months after therapy completion 1
• Very premature infants (≤28 weeks gestation) - Not contraindicated, but consider apnea risk and respiratory monitoring for 48-72 hours, particularly those with previous respiratory immaturity 1